Biointron's RushDATA™ Supports Molence Bio as Open-Source Mol-1 Takes Off

November 10, 2026 — Biointron Biological USA Inc. ("Biointron") is pleased to have contributed to Molence Bio's Mol-1 project. Mol-1 matches leading closed-source IsoDDE on antibody-antigen structure prediction and can be used to design functional nanobodies from scratch. To show those designs can become real drug candidates, Biointron ran the developability assays using RushDATA™, our wet-lab validation service for AI-designed antibodies.

The results: 23 of 30 AI-designed candidates met at least three of four developability criteria.

Wet-Lab Validation by Biointron

An AI-designed antibody needs lab data to prove it can become a drug. Biointron ran the developability panel on Molence Bio's VHH-Fc candidates, measuring properties that predict manufacturability and safety, including hydrophobicity, thermal stability, self-interaction, and non-specific binding. 

Each assay was benchmarked against Biointron reference antibodies, including infliximab, bevacizumab, bococizumab, gantenerumab, and trastuzumab, so the designs could be compared directly with approved and clinical-stage antibodies. 

Closing the Loop Between AI and the Lab

RushDATA™ is Biointron's wet-lab validation service for AI-designed antibodies:

• Speed: sequence to data in 2 days with cell-free expression or 3 days with CHO expression

• Scale: 10,000+ antibodies per day 

• Binding: multi-point affinity by BLI or SPR 

• Developability: DSF, PSR-BVP and AC-SINS profiling 

• AI-ready output: structured, model-ready datasets with API access, so results flow straight back into design models

Why It Matters

AI can now generate antibody binders at scale. The next challenge is proving which designs work in the lab and behave like drugs. Mol-1 shows what happens when a strong open model meets high-quality experimental data, and Biointron is proud to provide that data. 

Biointron congratulates Molence Bio on the launch of Mol-1 and looks forward to supporting the researchers who build on it. 

About Biointron

Founded in 2012, Biointron is a global antibody discovery CRO trusted by 3,000+ organizations in 20+ countries and regions, including top 20 pharma companies. Our RushDATA™ platform generates wet-lab data for AI-designed antibodies at scale, expressing 10,000+ antibodies a day and delivering binding and developability results in as little as 2 days, ready to feed your models via API. We also offer end-to-end antibody services from discovery to large-scale production, including our CHOK1BN cell line, already supporting partner programs in clinical trials. 

Learn more about RushDATA™: https://www.biointron.com/antibody-production/rushdata.html

About Molence Bio

Molence Bio is an AI-native biotech built on their own biomolecular foundation models. Their biologists, chemists, and AI researchers work side by side to advance these models and apply them to drug discovery: unlocking targets long considered undruggable, designing better molecules, and building a pipeline of therapies for unmet medical needs. 

Access the model weights: https://github.com/molence/Mol-1